Harold Bernstein - Sep 22, 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
President, R&D & CMO
Signature
/s/ Courtney Phillips, as attorney-in-fact
Stock symbol
MAZE
Transactions as of
Sep 22, 2025
Transactions value $
$0
Form type
4
Date filed
9/24/2025, 04:24 PM
Previous filing
Jan 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bernstein Harold President, R&D & CMO C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO /s/ Courtney Phillips, as attorney-in-fact 2025-09-24 0002050172

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MAZE Restricted Stock Units Award $0 +40K $0.00 40K Sep 22, 2025 Common Stock 40K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 The award shall vest as to 1/2 of the total award on September 1, 2026 and September 1, 2027, subject to the reporting person's continued service to the Issuer on each vesting date.
F3 These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.